Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001708138-22-000028 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-23 | 2022-03-21 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $691.31 | -312 | 28.7K | -1% | -$215.7K |
| D | 2022-03-23 | 2022-03-21 | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $693.00 | -300 | 28.7K | -1% | -$207.9K |
| D | 2022-03-23 | 2022-03-21 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +400 | 29.1K | +1% | +$152.8K |
| D | 2022-03-23 | 2022-03-21 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -400 | 18.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-21 | F | D | 312 | $691.31 | 28,744 | D | — | — | |
| 2 | Common | Common Stock | 2022-03-21 | S | D | 300 | $693.00 | 28,656 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-21 | M | A | 400 | $381.92 | 29,056 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-03-21 | M | D | 400 | $0.00 | 18,800 | D | $381.92 · — to 2026-12-16 | 400 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |